Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin

Completed · Phase 3

Conditions studied: Venous Thromboembolism

In brief

The purpose of this study is to assess if 10 mg BAY 59-7939, taken once daily as a tablet, is safe and prevent blood clot which may form after total hip replacement operation.

Key facts

Study ID

NCT00329628

Run by

Bayer

People needed

4541

Starts

2006-02-01

Expected to finish

2007-03-01

Last updated by the study team

2014-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients aged 18 years or above
• Patients scheduled for elective total hip replacement

You may not qualify if…

• Planned, staged total bilateral hip replacement
• Active bleeding or high risk of bleeding contraindicating treatment with low molecular weight heparin
• Contraindication listed in the labeling or conditions precluding patient treatment with enoxaparin
• Conditions prohibiting bilateral venography (e.g. amputation of one leg, allergy to contrast media)

Where it is running

• Study site — Northport, Alabama, United States
• Study site — Phoenix, Arizona, United States
• Study site — Benton, Arkansas, United States
• Study site — La Jolla, California, United States
• Study site — Aurora, Colorado, United States
• Study site — Decatur, Georgia, United States
• Study site — Missoula, Montana, United States
• Study site — Charleston, South Carolina, United States
• Study site — Dallas, Texas, United States
• Study site — Grapevine, Texas, United States
• Study site — Lubbock, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Avellaneda, Buenos Aires, Argentina
• Study site — Berazategui, Buenos Aires, Argentina
• Study site — Buenos Aires, Buenos Aires F.D., Argentina
• Study site — Buenos Aires, Buenos Aires F.D., Argentina
• Study site — Buenos Aires, Buenos Aires F.D., Argentina
• Study site — Buenos Aires, Buenos Aires F.D., Argentina
• Study site — Buenos Aires, Buenos Aires F.D., Argentina
• Study site — Sydney, New South Wales, Australia
• Study site — Adelaide, South Australia, Australia
• Study site — Melbourne, Victoria, Australia
• Study site — Melbourne, Victoria, Australia
• Study site — Fremantle, Western Australia, Australia
• Study site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.